Orexia is developing orexin receptor agonists for the treatment of narcolepsy, a rare neurological condition that affects the brain's ability to regulate the normal sleep-wake cycle
Orexin, also called ‘hypocretin’, is a key regulator of wakefulness and REM sleep. We aspire to develop innovative medicines that address the full spectrum of orexin dysfunction in disease areas where there is high unmet clinical need. Orexia is designing novel oral small molecule OX2R agonists and positive modulators, which would influence orexin neurotransmission differently.
Orexin agonists and positive modulators have the potential to treat a wide range of disorders which are inadequately treated today, most notably Narcolepsy Type 1 (NT1) which is caused by profound loss of orexin-producing neurons. NT1 is a chronic rare disease that usually starts during adolescence and is estimated to effect over 3 million people worldwide. Orexin agonists and positive modulators will directly address the underlying disease pathology of NT1, and may have the potential for greater efficacy and tolerability than current therapies.
Orexia is founded by Medicxi in collaboration with Sosei Heptares and leverages their unique GPCR structure-based drug design (SBDD) capability for the discovery and development of promising drug candidates.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 24 Chiswell Street, London,england Ec1y4yx,united Kingdom
- in****@****xia.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- orexiatherapeutics.com
- HQ
- London, England
Orexia Therapeutics Questions
Orexia Therapeutics's website is orexiatherapeutics.com
Orexia Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/orexiatherapeutics
Orexia Therapeutics has
6 employees.
View email and phone details for 6
employees at Orexia Therapeutics.
Orexia Therapeutics's industry is
Biotechnology Research
Orexia Therapeutics's top competitors are
Centessa Pharmaceuticals,
Mosaic Tx,
Kumuda,
Dalriada Drug Discovery,
Sandexis,
Talent Therapeutics,
Purespring Therapeutics,
Dunad Therapeutics,
Nuntius Therapeutics,
Multiomic Health.
Orexia Therapeutics's support email address is info@orexia.com
Orexia Therapeutics's categories are Biotechnology Research
Orexia Therapeutics's founding year is 2019
